Sensiotec Inc. www.Sensiotec.com, www.twitter.com/Sensiotec an innovator in biosensor and digital health technology and WellStar’s http://wellstar,org Center for Health Transformation http://centerforhealthtransformation.org (CHT) have agreed to accelerate the commercial adoption of the first FDA-approved contact free monitoring platform referred to as the Virtual Medical Assistant® (VMA).
CHT was acquired by WellStar in 2012 and as a partnership-based organization has established a new business partnership with Sensiotec. This was accomplished by evaluating 60 technology companies where the companies competed for the opportunity to team with WellStar. After careful consideration, CHT chose to partner with Sensiotec
VMA provides non-contact, continuous, remote monitoring of heart and respiratory rates, torso and limb movement, and bed occupancy without using electrodes or tape. The system is a scalable, high value, low cost, continuous surveillance solution that captures large data sets over long periods of time. The system is able to identify trends that can provide predictive insight into the clinical status of a patient and support early intervention to diagnose and treat incipient health threats.
From a thin sensor panel that simply slides under a mattress, bed, or chair, VMA sends continuous vital signs and motion data through its fully integrated patient monitoring platform to any number of nurses’ stations, tablets, or smartphones. VMA is able to identify whether a patient is experiencing deteriorating heart and respiratory readings, is a fall risk, or requires ulcer prevention management.
Built in patient management tools enables a caregiver to establish norms for each patient and set customized visual and audible alerts. With no uncomfortable electrodes attached to the skin, the technology offers convenience and comfort with no patient cooperation required. At the same time, it provides clinical documentation, increases labor productivity, reduces costs, and in some cases, may even help increase hospital revenue.
CHT has plans to test VMAs in diverse clinical settings and applications, such as sleep labs, pediatric units, post hospital discharge home care, cardiac rehab home care, and for nursing home resident monitoring.